Key result
Theoretical development of class IIIA antiarrhythmic agents suggests they should ideally lengthen refractoriness upon heart acceleration to exceed the tachycardia cycle length.
Proposes theoretical mechanisms for developing Class IIIA antiarrhythmic agents that increase refractoriness during tachycardia rather than bradycardia.
Answers are grounded in this paper and cite their sources.
Theoretical target for class IIIA agents guides preclinical design; leaves open clinical translation and safety.
Summary: Currently available antiarrhythmic agents that act by lengthening the action potential duration and refractory period exert most of their effect during bradycardia (class IIIB). Unfortunately, when these agents are most needed, i.e., during tachycardia, they lose most of their effect. In my opinion, ideally, antiarrhythmic agents need not change the electrophysiology of the normal sinus beat, but should lengthen refractoriness upon acceleration (class IIIA) of the heart until the refractory period exceeds the cycle length of the tachycardia. Three examples of how such class IIIA effects can be achieved are: (i) an upstroke-dependent activator of inward currents could form a universal class IIIA agent, (ii) a usedependent blocker of i To could be a great class IIIA agent in the atria, and (iii) a frequency-dependent blocker of late repolarizing currents (e.g., iks) could be a good target for a ventricular agent.
No takes yet. Share an insight, caveat, or question.
Luc M. Hondeghem (1992) conducted a review in Arrhythmia. Class IIIA antiarrhythmic agents was evaluated. Theoretical development of class IIIA antiarrhythmic agents suggests they should ideally lengthen refractoriness upon heart acceleration to exceed the tachycardia cycle length.
Synapse has enriched 10 related papers. Consider them for comparative context: